We have attempted to produce the 138-kDa early protein (ep 138) of Epstein-Barr virus (EBV) in Escherichia coli. This protein was found, by immunoprecipitation, to be a clinically relevant antigen, especially for the determination of the IgA-titer in patients with nasopharyngeal carcinoma (NPC). Since the expression of the entire ep 138 coding region was unsuccessful, we synthesized only the antigenic parts of this protein. Potential antigenic sites were predicted from the amino acid sequence by combining values for hydrophilicity with calculated estimates of the secondary structure. The two predicted fragments were found to be antigenic, but only one of them was stably expressed in E. coli as a non-fusion protein. This stable protein fragment was, in turn, able to stabilize the second antigenic fragment forming an autologous fusion protein, consisting exclusively of EBV-derived sequences. The resulting product reacts particularly well with IgA antibodies of NPC patients indicating its diagnostic value for NPC.